Scholarlink

<p>Purpose: To evaluate the efficacy of 8% arginine-based desensitizing toothpaste and photobiomodulation (PBM), used alone or in combination, in the treatment of dentin hypersensitivity (DH). Materials and methods: This randomized, double-blind, parallel-group clinical trial included participants with DH who were allocated into four groups: laser group (LG), arginine group (AG), combined laser and arginine group (LAG), and control group (CG). Clinical assessments were performed at baseline and after 2, 4, and 8 weeks. DH was evaluated using evaporative (air stimulus) and tactile tests applied to the cervical-buccal surface of the teeth, with pain intensity recorded using the Visual Analog Scale (VAS). Linear mixed-effects models were used for longitudinal continuous outcomes (Schiff and VAS scores), while generalized estimating equations were applied for tactile sensitivity outcomes, adopting a significance level of 5%. Results: A total of 60 participants were enrolled, and 54 completed the study. A significant reduction in DH was observed over time for both Schiff scores and VAS values (p &lt; 0.001). Mean Schiff scores decreased from 5.0 (± 0.8) at baseline to 1.9 (± 1.3) at 8 weeks, while VAS scores also showed significant reductions. All groups demonstrated improvement in DH symptoms; however, no statistically significant differences were observed between interventions at any time point (p &gt; 0.05). Conclusions: All evaluated therapies were effective in reducing DH over the 8-week follow-up period, with a progressive reduction in symptoms over time. However, no statistically significant differences were observed between the interventions, and no additive effect was identified for the combined therapy. Clinical trial registration: Brazilian Clinical Trials Registry ReBEC; RBR2vxzvkz, October 13<sup>th</sup>, 2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of 8% arginine associated with low-level laser therapy in the treatment of dentin hypersensitivity: randomized double-blind clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Viviane Leal Barbosa,
  • Djuly Westenhofen,
  • Paola Scherdien Silva,
  • Roberto Zimmer,
  • Harry Rivera Oballe,
  • Sergio Augusto Quevedo Miguens Júnior,
  • Eduardo Galia Reston

摘要

Purpose: To evaluate the efficacy of 8% arginine-based desensitizing toothpaste and photobiomodulation (PBM), used alone or in combination, in the treatment of dentin hypersensitivity (DH). Materials and methods: This randomized, double-blind, parallel-group clinical trial included participants with DH who were allocated into four groups: laser group (LG), arginine group (AG), combined laser and arginine group (LAG), and control group (CG). Clinical assessments were performed at baseline and after 2, 4, and 8 weeks. DH was evaluated using evaporative (air stimulus) and tactile tests applied to the cervical-buccal surface of the teeth, with pain intensity recorded using the Visual Analog Scale (VAS). Linear mixed-effects models were used for longitudinal continuous outcomes (Schiff and VAS scores), while generalized estimating equations were applied for tactile sensitivity outcomes, adopting a significance level of 5%. Results: A total of 60 participants were enrolled, and 54 completed the study. A significant reduction in DH was observed over time for both Schiff scores and VAS values (p < 0.001). Mean Schiff scores decreased from 5.0 (± 0.8) at baseline to 1.9 (± 1.3) at 8 weeks, while VAS scores also showed significant reductions. All groups demonstrated improvement in DH symptoms; however, no statistically significant differences were observed between interventions at any time point (p > 0.05). Conclusions: All evaluated therapies were effective in reducing DH over the 8-week follow-up period, with a progressive reduction in symptoms over time. However, no statistically significant differences were observed between the interventions, and no additive effect was identified for the combined therapy. Clinical trial registration: Brazilian Clinical Trials Registry ReBEC; RBR2vxzvkz, October 13th, 2023.